Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

Rhea-AI Summary

Crinetics Pharmaceuticals (CRNX) has announced its participation in two major healthcare investor conferences in March 2025. The company will be present at the TD Cowen 45th Annual Healthcare Conference in Boston, where management will participate in a fireside chat on March 3 at 11:10 a.m. ET. Additionally, they will attend the Leerink Global Healthcare Conference in Miami, featuring another fireside chat on March 10 at 4:20 p.m. ET.

Both events will be available via webcast, with live and archived versions accessible through the Events & Presentations page in the Investors section of Crinetics' website. Investors interested in one-on-one meetings with management are encouraged to contact their conference representatives.

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL.

TD Cowen 45th Annual Healthcare Conference
          Fireside chat on Monday, March 3, 2025 at 11:10 a.m. Eastern Time
          Webcast link HERE

Leerink Global Healthcare Conference
          Fireside chat on Monday, March 10, 2025 at 4:20 p.m. Eastern Time
          Webcast link HERE

The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.

If you are interested in arranging a 1x1 meeting with management, please contact your conference representative.

ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist, that is currently in development for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

FAQ

When is Crinetics Pharmaceuticals (CRNX) presenting at the TD Cowen Healthcare Conference in March 2025?

Crinetics Pharmaceuticals will present at the TD Cowen Healthcare Conference on Monday, March 3, 2025, at 11:10 a.m. Eastern Time in Boston.

What time is CRNX's presentation at the Leerink Global Healthcare Conference?

CRNX will present at the Leerink Global Healthcare Conference on Monday, March 10, 2025, at 4:20 p.m. Eastern Time in Miami.

How can investors access CRNX's March 2025 conference presentations?

Investors can access both live and archived webcasts of the presentations through Crinetics' website at www.crinetics.com/events under the Events & Presentations page in the Investors section.

How can investors arrange one-on-one meetings with CRNX management at these conferences?

Investors interested in arranging one-on-one meetings with CRNX management should contact their conference representative directly.